Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03681483 · ClinicalTrials.gov registry record · Phase 1
RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03681483: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03681483 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03681483, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of RO5126766 at different doses to find out what effects, if any, it has on people with advanced lung cancer who have previously received treatment with a PD-1 or PD-L1 inhibitor.
Interventions
- DRUG RO5126766
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-10-31 |
| Est. Completion | 2024-07-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03681483
The ClinicalTrials.gov registry entry for NCT03681483 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RO5126766 is the first listed.
NCT03681483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03681483 about?
NCT03681483 is a clinical study titled "RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer". The purpose of this study is to test the safety of RO5126766 at different doses to find out what effects, if any, it has on people with advanced lung cancer who have previously received treatment with a PD-1 or PD-L1 inhibitor.
What is the current status of trial NCT03681483?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2018-10-31. Estimated completion is 2024-07-08.
What interventions are being tested in trial NCT03681483?
The interventions under investigation include: RO5126766 (DRUG).
Who is sponsoring clinical trial NCT03681483?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.